This randomized, double-blind, placebo-controlled, parallel-group study evaluated the
efficacy and safety of single daily dose diltiazem extended-release (XR) and indapamide …

Although calcium channel blockers were only recently approved for antihypertensive
therapy, 10 years of data have demonstrated their beneficial effects. Among the available …

Twelve patients with mild to moderate essential hypertension were included in a double-
blind, balanced, randomized placebo-controlled cross-over study to assess the efficacy and …

The efficacy and safety of optimally titrated once-daily (CD) and twice-daily (SR) diltiazem
were compared in 111 patients with mild to moderate systemic hypertension [seated …

Thirty patients (17 females, median age 55 years) with mild/moderate hypertension (sitting
diastolic blood pressure 95-110 mmHg over 2 consecutive weeks) participated in a study of …

The safety and efficacy of an extended-release form of diltiazem HCl (diltiazem XR) in
patients 55 years or older with mild-to-moderate essential hypertension were examined in a …

This study assessed once-daily sustained-release (od SR) diltiazem in essential
hypertension; 158 patients with supine diastolic blood pressures (BP) of 95-115 mm Hg …

A new polymeric matrix technology provides a sustained‐release formulation of diltiazem
hydrochloride (diltiazem SR) suitable for once‐daily therapy. The efficacy and safety of …

The objective was to evaluate the dose-related efficacy/tolerance profile of 240, 300, 360,
and 420 mg diltiazem slow-release, once-daily (OD) doses, with emphasis on the 300 mg …

In a double-blind study, patients with mild-to-moderate hypertension were randomly
assigned to receive placebo or increasing daily doses of a new sustained-release …